Clinical Trial

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Study acronym: FRIENDS-01
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 14, 2026 (before its estimated April 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-29.
Status change: Not Yet Recruiting → Recruiting 2026-04-09
Trial Details
NCT Number NCT06759636
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions CTIT: Cancer Therapy Induced Thrombocytopenia
Enrollment 88 participants
Start Date 2025-02-24
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-14